pertussis fimbrial agglutinogen 2 + pertussis fimbrial agglutinogen 3

Pertussis fimbrial agglutinogen 2 + pertussis fimbrial agglutinogen 3 is a combination of two purified protein subunits derived from the bacterium *Bordetella pertussis*, used as essential components in multi-antigen acellular pertussis (aP) vaccines. Fimbriae, also known as agglutinogens, are filamentous surface structures that play a critical role in bacterial adhesion to the ciliated respiratory epithelium, a key step in the pathogenesis of whooping cough. By including both serotypes 2 and 3 (FIM2 and FIM3), vaccines aim to provide broader protective immunity against various circulating strains of *B. pertussis*. This combination is typically formulated alongside other antigens such as pertussis toxoid, filamentous hemagglutinin, and pertactin, often within diphtheria, tetanus, and pertussis (DTaP/Tdap) vaccines. The University of Antwerp has been a leading institution in the clinical evaluation of these multi-component vaccines, contributing to research on their efficacy in infants and their role in maternal immunization programs to protect newborns.

Other names

Fimbriae types 2 and 3Agglutinogens 2 and 3Agglutinogens2 and 3Agglutinogens-2 and 3